RxDoctor Payments Data

Ramy Hanna, MD

Clinical Cardiac Electrophysiology · Mount Vernon, WANPI 1073732418

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (36.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Siemens Medical Solutions USA, Inc. at 48.0% of the total. Reporting peaked in 2024 at $3,451 and has fallen 86.2% since, to $475 in 2025.

$10,113in general payments, 2019–2025

Across 80 payments — averaging $126.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Siemens Medical Solutions USA, Inc.$5K
  • Abbott$2K
  • Biosense Webster, Inc.$1K
  • Medical Device Business Services, Inc.$411
  • Boston Scientific$287
  • Medtronic$272
  • plus $705 from 9 others

What the payments were for

  • Consulting fees$3,69537%
  • Speaking & faculty fees$1,16011%
  • Travel & lodging$1,74717%
  • Food & beverage$3,51135%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,113 in reported general payments places this provider in the 55th percentile of 68 clinical cardiac electrophysiology providers in Washington.

See all clinical cardiac electrophysiology providers in Washington

Medicare billing

Part B allowed, 2024
$291,610
Medicare patients
774
Services billed
3,480

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban446$565,862
XareltoRivaroxaban205$260,769
JardianceEmpagliflozin13$18,790
Dofetilide64$18,102
Flecainide Acetate342$15,397
EntrestoSacubitril/Valsartan21$14,106
Metoprolol Succinate605$12,085
PradaxaDabigatran Etexilate Mesylate31$10,951
Amiodarone Hcl198$5,228
Diltiazem 24hr Er (Cd)Diltiazem Hcl131$4,158
Potassium Chloride110$3,752
Dabigatran EtexilateDabigatran Etexilate Mesylate13$3,136
SotalolSotalol Hcl70$2,282
Atorvastatin Calcium137$1,775
Mexiletine Hcl21$1,680

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$25$260,769205 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 68 clinical cardiac electrophysiology providers in Washington.

Other clinical cardiac electrophysiology in Mount Vernon

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →